Olonase (25 mcg+600 mcg)/Spray

Olonase (25 mcg+600 mcg)/Spray | INDICATIONS AND USES

This preparation nasal spray is indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older.

Olonase (25 mcg+600 mcg)/Spray | PHARMACOLOGY

This is a metered-dose manual nasal spray unit containing an aqueous suspension of a fixed-dose combination of a olopatadine hydrochloride and mometasone furoate monohydrate.Olopatadine is a histamine-1 (H1) receptor inhibitor. The antihistaminic activity of olopatadine has been documented in isolated tissues, animal models, and humans.Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of inhibitory effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation.

Olonase (25 mcg+600 mcg)/Spray | DOSAGE

Adults and Adolescents (12 years of age and older): The recommended dosage of Olonase is 2 sprays in each nostril twice daily.Children (6 to 11 years of age): The recommended dosage of Olonase is 1 spray in each nostril twice daily.For nasal use only. Shake the bottle well before each use. Avoid spraying into the eyes or mouth. See illustrated patient’s instructions for proper use of Nasal Spray. Read the complete instructions carefully and use only as directed.

Olonase (25 mcg+600 mcg)/Spray | DRUG INTERACTIONS

Concurrent use of this combination with alcohol or other central nervous system depressants should be avoided because somnolence and impairment of central nervous system performance may occur. Concomitant administration of CYP3A4 inhibitors may inhibit the metabolism of, and increase the mometasone furoate plasmaconcentration and potentially increase the risk for adverse reactions. Caution should be exercised when considering the coadministration of this combination with strong CYP3A4 inhibitors.

Olonase (25 mcg+600 mcg)/Spray | SIDE EFFECTS

Common side effects are-

Dysgeusia
Epistaxis
Nasal discomfort

The following clinically significant adverse reactions are described-

Local Nasal Adverse Reactions
Somnolence and Impaired Mental Alertness
Glaucoma and Cataracts
Hypersensitivity Reactions
Immunosuppression and Risk of Infections
Hypercorticism and Adrenal Suppression

Olonase (25 mcg+600 mcg)/Spray | USE DURING PREGNANCY AND LACTATION

There are no available data of mometasone furoate use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcome. There are no available data on the presence of olopatadine or mometasone furoate or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Other corticosteroids similar to mometasone furoate, are excreted in human milk. However, mometasone furoate concentrations in plasma after nasal therapeutic doses are low and therefore concentrations in human breast milk are likely to be correspondingly low.

Olonase (25 mcg+600 mcg)/Spray | PRECAUTIONS & WARNINGS

Epistaxis, nasal ulcerations, nasal septal perforations, impaired wound healing, and Candida albicans infection: Monitor patients periodically for signs of adverse reactions on the nasal mucosa.Somnolence: Avoid engaging in hazardous occupations requiring complete mental alertness and motor coordination such as driving or operating machinery when taking this nasal spray.Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with this nasal spray because additional reductions in alertness and additional impairment of CNS performance may occur.Glaucoma and cataracts: Monitor patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.Hypersensitivity Reactions: Hypersensitivity reactions can occur with this nasal spray. Hypersensitivity reactions including wheezing, have occurred after the nasal administration of mometasone furoate. Discontinue this nasal spray if such reactions occur.Immunosuppression and Risk of Infections: Potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. More serious or even fatal course of chickenpox or measles in susceptible patients: Use caution in patients with the above because of the potential for worsening of these infections.Hypercorticism and adrenal suppression with misuse or use of higher- than-recommended dosages or at the regular dosage in susceptible patients at risk for such effects.Potential reduction in growth velocity in children: Routinely monitor the growth in pediatric patients receiving this nasal spray.

Olonase (25 mcg+600 mcg)/Spray | STORAGE CONDITIONS

Do not store above 25°C temperature. Do not refrigerate. Keep away from light and wet place. Keep out of reach of children.